Mark E. Cooper
About
Mark E. Cooper is a scholar working on Endocrinology, Diabetes and Metabolism, Nephrology and Cardiology and Cardiovascular Medicine.
According to data from OpenAlex, Mark E. Cooper has authored 514 papers receiving a total of 48.8k indexed citations (citations by other indexed papers that have themselves been cited), including 205 papers in Endocrinology, Diabetes and Metabolism, 197 papers in Nephrology and 144 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Mark E. Cooper's work include Chronic Kidney Disease and Diabetes (180 papers), Advanced Glycation End Products research (134 papers) and Diabetes Treatment and Management (108 papers). Mark E. Cooper is often cited by papers focused on Chronic Kidney Disease and Diabetes (180 papers), Advanced Glycation End Products research (134 papers) and Diabetes Treatment and Management (108 papers). Mark E. Cooper collaborates with scholars based in Australia, United States and United Kingdom. Mark E. Cooper's co-authors include Josephine M. Forbes, Merlin C. Thomas, Karin Jandeleit‐Dahm, Dick de Zeeuw, Giuseppe Remuzzi, Shahnaz Shahinfar, Barry M. Brenner, William F. Keane, Hans‐Henrik Parving and William E. Mitch and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.
In The Last Decade
Mark E. Cooper
501 papers receiving 47.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mark E. Cooper Australia | 109 | 17.9k | 13.2k | 12.7k | 11.6k | 8.5k | 514 | 48.8k | ||
| Peter Rossing Denmark | 88 | 23.0k 1.3× | 11.0k 0.8× | 10.7k 0.8× | 8.5k 0.7× | 1.8k 0.2× | 751 | 40.8k | ||
| Christoph Wanner Germany | 90 | 17.9k 1.0× | 14.1k 1.1× | 8.4k 0.7× | 9.5k 0.8× | 1.3k 0.2× | 716 | 46.4k | ||
| Eberhard Ritz Germany | 97 | 9.4k 0.5× | 19.5k 1.5× | 13.8k 1.1× | 6.5k 0.6× | 1.5k 0.2× | 934 | 44.8k | ||
| William E. Mitch United States | 81 | 6.0k 0.3× | 11.4k 0.9× | 7.9k 0.6× | 11.1k 1.0× | 1.6k 0.2× | 312 | 37.4k | ||
| Barry M. Brenner United States | 91 | 8.6k 0.5× | 15.1k 1.1× | 13.0k 1.0× | 7.8k 0.7× | 1.4k 0.2× | 296 | 39.7k | ||
| Ann Marie Schmidt United States | 113 | 11.7k 0.7× | 3.4k 0.3× | 3.6k 0.3× | 13.3k 1.1× | 27.6k 3.3× | 395 | 49.7k | ||
| James R. Sowers United States | 95 | 14.8k 0.8× | 3.3k 0.3× | 15.6k 1.2× | 10.0k 0.9× | 1.0k 0.1× | 689 | 42.7k | ||
| George L. King United States | 90 | 7.3k 0.4× | 1.9k 0.1× | 4.9k 0.4× | 12.6k 1.1× | 3.9k 0.5× | 276 | 32.5k | ||
| Rhian M. Touyz Canada | 104 | 7.5k 0.4× | 2.2k 0.2× | 12.6k 1.0× | 11.0k 0.9× | 1.2k 0.1× | 522 | 37.0k | ||
| Johannes F.E. Mann Germany | 66 | 13.9k 0.8× | 9.3k 0.7× | 10.5k 0.8× | 5.1k 0.4× | 483 0.1× | 277 | 30.0k |
Countries citing papers authored by Mark E. Cooper
Since
Specialization
Citations
This map shows the geographic impact of Mark E. Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Cooper more than expected).
Fields of papers citing papers by Mark E. Cooper
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mark E. Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Cooper. The network helps show where Mark E. Cooper may publish in the future.
Co-authorship network of co-authors of Mark E. Cooper
This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Cooper. A scholar is included among the top collaborators of Mark E. Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Cooper. Mark E. Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Thallas‐Bonke, Vicki, Matthew Snelson, Karly C. Sourris, et al.. (2025). Proximal tubular deletion of superoxide dismutase-2 reveals disparate effects on kidney function in diabetes. Redox Biology. 82. 103601–103601.
2.
Bonnet, Fabrice, Mark E. Cooper, Laetitia Koppe, Denis Fouque, & Riccardo Candido. (2024). A review of the latest real‐world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?. Diabetes Obesity and Metabolism. 26(S6). 55–65.
3.
Schlaich, Markus P., Konstantinos Tsioufis, Stefano Taddei, et al.. (2024). Targeting the sympathetic nervous system with the selective imidazoline receptor agonist moxonidine for the management of hypertension: an international position statement. Journal of Hypertension. 42(12). 2025–2040.
4.
Hadjadj, Samy, Mark E. Cooper, Dominik Steubl, et al.. (2023). Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial. Kidney Medicine. 6(3). 100783–100783.
5.
Thomas, Merlin C., Brendon L. Neuen, Stephen M. Twigg, Mark E. Cooper, & Sunil V. Badve. (2023). SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review. Endocrine Connections. 12(8).
6.
Chai, Zhonglin, Mark E. Cooper, Paul Zimmet, et al.. (2022). Elevated Fasting Blood Glucose Levels Are Associated with Worse Clinical Outcomes in COVID-19 Patients Than in Pneumonia Patients with Bacterial Infections. Pathogens. 11(8). 902–902.
7.
Liu, Jinli, Ruhai Bai, Zhonglin Chai, et al.. (2022). Low- and middle-income countries demonstrate rapid growth of type 2 diabetes: an analysis based on Global Burden of Disease 1990–2019 data. Diabetologia. 65(8). 1339–1352.
8.
Tan, Sih Min, Runa Lindblom, Mark Ziemann, et al.. (2021). Targeting Methylglyoxal in Diabetic Kidney Disease Using the Mitochondria-Targeted Compound MitoGamide. Nutrients. 13(5). 1457–1457.
9.
McGuire, Darren K., John H. Alexander, Odd Erik Johansen, et al.. (2019). Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 139(3). 351–361.
10.
Ohkuma, Toshiaki, Min Jun, Anthony Rodgers, et al.. (2018). Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus. Hypertension. 73(1). 84–91.
11.
Pickering, R. J., Christos Tikellis, Carlos J. Rosado, et al.. (2018). Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis. Journal of Clinical Investigation. 129(1). 406–421.
12.
Ng, M., John Chalmers, Mark Woodward, et al.. (2013). The Association of High-Density Lipoprotein Cholesterol with Cancer Incidence in Type II Diabetes: A Case of Reverse Causality?. Cancer Epidemiology Biomarkers & Prevention. 22(9). 1628–1633.
13.
Wilkinson‐Berka, Jennifer L., Devy Deliyanti, Indrajeetsinh Rana, et al.. (2013). NADPH Oxidase, NOX1, Mediates Vascular Injury in Ischemic Retinopathy. Antioxidants and Redox Signaling. 20(17). 2726–2740.
14.
Bakker, Stephan J. L., Gozewijn D. Laverman, Tomás Berl, et al.. (2012). An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection. Journal of Hypertension. 30(5). 1022–1028.
15.
Packham, David, Jamie P. Dwyer, Robert C. Atkins, et al.. (2011). Relative Incidence of ESRD Versus Cardiovascular Mortality in Proteinuric Type 2 Diabetes and Nephropathy: Results From the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) Database. American Journal of Kidney Diseases. 59(1). 75–83.
16.
Thomas, Merlin C., R. J. Pickering, Despina Tsorotes, et al.. (2010). Genetic Ace2 Deficiency Accentuates Vascular Inflammation and Atherosclerosis in the ApoE Knockout Mouse. Circulation Research. 107(7). 888–897.
17.
Cooper, Mark E., et al.. (2010). I. A.C.C.E.P.T. M.E.: Strategies for Developing Self-Acceptance when Parenting Children Who Challenge.. Exceptional parent/The Exceptional parent. 40(12). 14–15.
18.
Dilley, Rodney J., Caroline A. Farrelly, Terri J. Allen, et al.. (2005). Diabetes induces Na/H exchange activity and hypertrophy of rat mesenteric but not basilar arteries. Diabetes Research and Clinical Practice. 70(3). 201–208.
19.
Forbes, Josephine M., Vicki Thallas‐Bonke, Mark E. Cooper, & Merlin C. Thomas. (2004). Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy. Current Pharmaceutical Design. 10(27). 3361–3372.
20.
Cooper, Mark E., et al.. (1986). Low serum C4 concentrations and microangiopathy in type I and type II diabetes.. BMJ. 292(6523). 801–801.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Peter Rossing Breakdown of academic impact, for papers by Christoph Wanner Breakdown of academic impact, for papers by Eberhard Ritz Breakdown of academic impact, for papers by William E. Mitch Breakdown of academic impact, for papers by Barry M. Brenner Breakdown of academic impact, for papers by Ann Marie Schmidt Breakdown of academic impact, for papers by James R. Sowers Breakdown of academic impact, for papers by George L. King Breakdown of academic impact, for papers by Rhian M. Touyz Breakdown of academic impact, for papers by Johannes F.E. Mann